Achiko AG (XSWX:ACHI) Gross-Profit-to-Asset % : 0.00% (As of Jun. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Achiko AG Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Achiko AG's annualized Gross Profit for the quarter that ended in Jun. 2022 was CHF0.00 Mil. Achiko AG's average Total Assets over the quarter that ended in Jun. 2022 was CHF2.02 Mil. Therefore, Achiko AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2022 was 0.00%.

Achiko AG Gross-Profit-to-Asset % Historical Data

The historical data trend for Achiko AG's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achiko AG Gross-Profit-to-Asset % Chart

Achiko AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Gross-Profit-to-Asset %

8.18

14.08

1.26

Achiko AG Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			24.59	-1.06	2.11	0.62	-

Competitive Comparison of Achiko AG's Gross-Profit-to-Asset %

For the Health Information Services subindustry, Achiko AG's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achiko AG's Gross-Profit-to-Asset % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Achiko AG's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Achiko AG's Gross-Profit-to-Asset % falls into.

Achiko AG Gross-Profit-to-Asset % Calculation

Achiko AG's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2021 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2021 )	/	( (Total Assets (A: Dec. 2020 )	+	Total Assets (A: Dec. 2021 ))	/ count )
	=	0.021	/	( (1.574	+	1.763)	/ 2 )
	=	0.021	/	1.6685
	=	1.26 %

Achiko AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2022 )	/	( (Total Assets (Q: Dec. 2021 )	+	Total Assets (Q: Jun. 2022 ))	/ count )
	=	0	/	( (1.763	+	2.278)	/ 2 )
	=	0	/	2.0205
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2022) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Achiko AG Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Achiko AG's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Achiko AG (XSWX:ACHI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (XSWX:ACHI) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tessinerplatz 7, Zurich, CHE, CH-8002

Website

https://www.achiko.com

Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Achiko AG (XSWX:ACHI) Headlines

No Headlines